Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 11/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29546918 | 0.84 | ATR (0.42) | LCKCA1CA12CA9CA2 | |
| SCHEMBL29955118 | 0.81 | RXFP1 (0.36) | LCKCA1CA12CA9CA2 | |
| SCHEMBL19260400 | 0.80 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL400755 | 0.80 | LCK (0.46) | LCKCA1CA12CA9CA2 | |
| SCHEMBL2824619 | 0.79 | NPSR1 (0.45) | ALDH1A1LCK | |
| SCHEMBL30590426 | 0.79 | SMN1; SMN2 (0.40) | ALDH1A1LCKCA1CA2 | |
| SCHEMBL6969183 | 0.77 | ALDH1A1 (0.44) | ALDH1A1CA1CA12CA9CYP17A1 | |
| SCHEMBL30590407 | 0.77 | LCK (0.40) | LCKCA1CA12CA9CA2 | |
| SCHEMBL23315799 | 0.75 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL2829793 | 0.74 | ALDH1A1 (0.56) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548899-B2 | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548899-B2 | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210188870-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188870-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3416969-B1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-13 | — | — | US | disclosed |
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-13 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| EP-3345906-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Wuxi Shuangliang Biotechnology Co., Ltd. (CN) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017142881-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017035753-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | 无锡双良生物科技有限公司 | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | ERBB2, EGFR, ERBB3 | ALDH1A1 3028/4885LCK 157/4885CA1 4881/4885 |
| US-20210188870-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | ALDH1A1 2498/4885LCK 1512/4885CA1 1643/4885 |
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | ERBB2, EGFR, ERBB3 | ALDH1A1 3053/4885LCK 126/4885CA1 4882/4885 |
| US-11548899-B2 | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors | BRD4, BRD3, BRD2 | ALDH1A1 2498/4885LCK 1512/4885CA1 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.